

**FORM 62-103F3**

**REPORT UNDER PART 4 OF  
NATIONAL INSTRUMENT 62-103**

**Item 1 – Security and Reporting Issuer**

- 1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

This report relates to the common shares ("**Common Shares**") in the capital of:

Poda Holdings, Inc. (formerly, Poda Lifestyle and Wellness Ltd.) (the "**Issuer**")  
Suite 2800, Park Place  
666 Burrard Street  
Vancouver, BC  
V6C 2Z7

- 1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

Canadian Securities Exchange ("**CSE**")

**Item 2 – Identity of the Eligible Institutional Investor**

- 2.1 State the name and address of the eligible institutional investor.

Armistice Capital, LLC ("**Armistice**")  
510 Madison Avenue  
7<sup>th</sup> Floor  
New York, NY 10022  
U.S.A.

- 2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

The requirement to file this report was triggered as of September 30, 2021 as a result of dispositions, throughout the month of September, of an aggregate of 840,800 Common Shares through the facilities of the CSE by Armistice, on behalf of an investment fund it manages

- 2.3 State the name of any joint actors.

Not applicable.

- 2.4 State that the eligible institutional investor is eligible to file reports under Part 4 in respect of the reporting issuer.

Armistice is eligible to file reports under Part 4 of National Instrument 62-103 (“**NI 62-103**”) in respect of securities of the Issuer.

### Item 3 – Interest in Securities of the Reporting Issuer

- 3.1 State the designation and the net increase or decrease in the number or principal amount of securities, and in the eligible institutional investor’s securityholding percentage in the class of securities, since the last report filed by the eligible institutional investor under Part 4 or the early warning requirements.

Since the last report dated September 10, 2021, Armistice, on behalf of an investment fund it manages, has disposed of an aggregate of 840,800 Common Shares, representing a net decrease of approximately 1.67% of the Issuer’s 50,197,229 issued and outstanding Common Shares as reported in its Management’s Discussion and Analysis dated July 28, 2021 and press release dated August 5, 2021 (the “**Outstanding Shares**”).

- 3.2 State the designation and number or principal amount of securities and the eligible institutional investor’s securityholding percentage in the class of securities at the end of the month for which the report is made.

As of September 30, 2021, Armistice, on behalf of an investment fund it manages, exercised control or direction over:

- (i) 6,212,000 Common Shares; and
- (ii) 7,500,000 Common Share purchase warrants of the Issuer (“**Warrants**”) at a price of \$2.00 per Common Share and associated Warrant for an aggregate purchase price of \$15,000,000. Each Warrant entitles the holder thereof to purchase an additional Common Share at a price of \$2.50 per Common Share at any time on or before August 5, 2024. The exercise right of the Warrants is subject to a beneficial ownership limitation which prohibits the holder to exercise any of the Warrants if such exercise would result in the holder holding greater than 9.99% of the issued and outstanding Common Shares of the Issuer following the exercise,

representing approximately 12.38% of the Outstanding Shares.

- 3.3 If the transaction involved a securities lending arrangement, state that fact.

Not applicable

3.4 State the designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities to which this report relates and over which

(a) the eligible institutional investor, either alone or together with any joint actors, has ownership and control,

Not applicable.

(b) the eligible institutional investor, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the eligible institutional investor or any joint actor, and

Not applicable.

(c) the eligible institutional investor, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.

Armistice exercises control or direction, but not ownership, over all of the securities referred to in items 2.2 and 3.2 above on behalf of an investment fund managed by it over which it has discretionary trading authority. Armistice specifically disclaims any beneficial ownership of the securities referred to herein.

3.5 If the eligible institutional investor or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the eligible institutional investor's securityholdings.

Not applicable.

3.6 If the eligible institutional investor or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement. State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.

Not applicable.

3.7 If the eligible institutional investor or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the eligible institutional investor's economic exposure to the security

of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.

Not applicable.

#### **Item 4 – Purpose of the Transaction**

State the purpose or purposes of the eligible institutional investor and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the eligible institutional investor and any joint actors may have which relate to or would result in any of the following:

- (a) the acquisition of additional securities of the reporting issuer, or the disposition of securities of the issuer;

The securities of the Issuer were acquired for investment purposes. Depending on market conditions and other factors, Armistice, on behalf of the investment fund managed by it, may in the future increase or decrease its ownership, control or direction over securities of the Issuer through open market transactions, private agreements or otherwise.

- (b) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;

Not applicable.

- (c) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;

Not applicable.

- (d) a material change in the present capitalization or dividend policy of the reporting issuer;

Not applicable.

- (e) a material change in the reporting issuer's business or corporate structure;

Not applicable.

- (f) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person;

Not applicable.

- (g) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;

Not applicable.

- (h) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;

Not applicable.

- (i) a solicitation of proxies from securityholders;

Not applicable.

- (j) an action similar to any of those enumerated above.

Not applicable.

#### **Item 5 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer**

Describe the material terms of any agreements, arrangements, commitments or understandings between the eligible institutional investor and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

Not applicable.

#### **Item 6 – Change in Material Fact**

If applicable, describe any change in a material fact set out in a previous report filed by the eligible institutional investor under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

Not applicable.

**Item 7 – Certification**

The undersigned, as the eligible institutional investor, certifies, or the undersigned, as the agent filing the report on behalf of the eligible institutional investor, certifies to the best of its knowledge, information and belief, that the statements made in this report are true and complete in every respect.

**DATED** this 8th day of October, 2021.

**ARMISTICE CAPITAL, LLC**

By: "Brian Kohn"  
Brian Kohn  
General Counsel and Chief  
Compliance Officer